Stephen From - 02 Jul 2021 Form 4 Insider Report for EYEGATE PHARMACEUTICALS INC (KPRX)

Reporting relationship: Executive Chairman, Director
Issuer ticker: KPRX
Reported as of: 02 Jul 2021
Net transaction value: -$3,245
SEC form: 4
Accepted by SEC: 06 Jul 2021, 16:31:12 UTC
Prior SEC filing: 07 Jun 2021
Next SEC filing: 04 Aug 2021
Source filing: View source filing
Reporting owner signature: /s/ Sarah Romano, Attorney-in-Fact*

Key filing fact

Stephen From filed Form 4 for EYEGATE PHARMACEUTICALS INC (KPRX) on 06 Jul 2021.

Key facts

This page summarizes Stephen From's Form 4 filing for EYEGATE PHARMACEUTICALS INC (KPRX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 06 Jul 2021, 16:31.

Change

Previous filing in this sequence was filed on 07 Jun 2021.
Current net transaction value: -$3,245.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KPRX transaction

Common Stock

Tax liability

Transaction value: $3,245
Shares: -877
Change %: -1.2%
Price: $3.70
Shares after: 69,305
Date: 02 Jul 2021
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Sale of shares to cover taxes due on restricted stock that vested on 07/01/2021.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.70 to $3.75, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC remarks

*Signed under power of attorney on behalf of Reporting Person